A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Everolimus (Primary) ; Pasireotide (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 29 Jan 2018 According to results published in the Melanoma Research, the study was terminated due to poor accrual.
- 29 Jan 2018 Status changed from active, no longer recruiting to discontinued, according to results published in the Melanoma Research.
- 16 Jun 2016 Status changed from active, no longer recruiting to completed.